NewAmsterdam Pharma (NAMS) Income from Continuing Operations (2023 - 2025)
Historic Income from Continuing Operations for NewAmsterdam Pharma (NAMS) over the last 3 years, with Q3 2025 value amounting to -$72.0 million.
- NewAmsterdam Pharma's Income from Continuing Operations fell 33254.04% to -$72.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$221.1 million, marking a year-over-year decrease of 1115.4%. This contributed to the annual value of -$241.6 million for FY2024, which is 3654.46% down from last year.
- Per NewAmsterdam Pharma's latest filing, its Income from Continuing Operations stood at -$72.0 million for Q3 2025, which was down 33254.04% from -$17.4 million recorded in Q2 2025.
- NewAmsterdam Pharma's 5-year Income from Continuing Operations high stood at -$16.6 million for Q3 2024, and its period low was -$93.8 million during Q1 2024.
- Over the past 3 years, NewAmsterdam Pharma's median Income from Continuing Operations value was -$42.0 million (recorded in 2023), while the average stood at -$49.8 million.
- Per our database at Business Quant, NewAmsterdam Pharma's Income from Continuing Operations skyrocketed by 6468.08% in 2024 and then plummeted by 33254.04% in 2025.
- Quarter analysis of 3 years shows NewAmsterdam Pharma's Income from Continuing Operations stood at -$49.5 million in 2023, then plummeted by 86.34% to -$92.2 million in 2024, then increased by 21.88% to -$72.0 million in 2025.
- Its Income from Continuing Operations was -$72.0 million in Q3 2025, compared to -$17.4 million in Q2 2025 and -$39.5 million in Q1 2025.